Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) was the target of a large drop in short interest in May. As of May 29th, there was short interest totaling 175,238 shares, a drop of 41.0% from the May 14th total of 296,872 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average trading volume of 292,130 shares, the short-interest ratio is currently 0.6 days.
Institutional Trading of Allarity Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of Allarity Therapeutics during the second quarter worth $27,000. XTX Topco Ltd acquired a new position in shares of Allarity Therapeutics during the fourth quarter worth $36,000. Geode Capital Management LLC lifted its holdings in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares during the period. Capital Advisors Inc. OK acquired a new position in shares of Allarity Therapeutics during the fourth quarter worth $108,000. Finally, DRW Securities LLC acquired a new position in shares of Allarity Therapeutics during the fourth quarter worth $133,000. Institutional investors and hedge funds own 11.53% of the company’s stock.
Allarity Therapeutics Trading Up 3.5%
Allarity Therapeutics stock traded up $0.05 during mid-day trading on Monday, reaching $1.48. The company had a trading volume of 46,008 shares, compared to its average volume of 185,097. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.35. The company has a market cap of $23.55 million, a P/E ratio of -2.06 and a beta of 0.52. The business has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $1.21.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. Finally, Ascendiant Capital Markets increased their price target on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.25.
Read Our Latest Stock Analysis on Allarity Therapeutics
Allarity Therapeutics Company Profile
Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.
The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.
Featured Stories
- Five stocks we like better than Allarity Therapeutics
- Iran Ceasefire or Not, These 3 Companies Could Win
- Gold Is Testing Its 200-Day SMA—These 3 Mining Stocks Are the Play
- Summer Is Coming–But There’s No End in Sight for This Crypto Winter
- Oil Could Dip, But These 3 Energy Stocks Still Look Built to Win
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
